Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.

Détails

ID Serval
serval:BIB_4A05961FDF32
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Périodique
Cancer Research
Auteur(s)
Dewaele B., Floris G., Finalet-Ferreiro J., Fletcher C.D., Coindre J.M., Guillou L., Hogendoorn P.C., Wozniak A., Vanspauwen V., Schöffski P., Marynen P., Vandenberghe P., Sciot R., Debiec-Rychter M.
ISSN
1538-7445[electronic], 0008-5472[linking]
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
70
Numéro
18
Pages
7304-7314
Langue
anglais
Résumé
Intimal sarcoma (IS) is a rare, malignant, and aggressive tumor that shows a relentless course with a concomitant low survival rate and for which no effective treatment is available. In this study, 21 cases of large arterial blood vessel IS were analyzed by immunohistochemistry and fluorescence in situ hybridization and selectively by karyotyping, array comparative genomic hybridization, sequencing, phospho-kinase antibody arrays, and Western immunoblotting in search for novel diagnostic markers and potential molecular therapeutic targets. Ex vivo immunoassays were applied to test the sensitivity of IS primary tumor cells to the receptor tyrosine kinase (RTK) inhibitors imatinib and dasatinib. We showed that amplification of platelet-derived growth factor receptor α (PDGFRA) is a common finding in IS, which should be considered as a molecular hallmark of this entity. This amplification is consistently associated with PDGFRA activation. Furthermore, the tumors reveal persistent activation of the epidermal growth factor receptor (EGFR), concurrent to PDGFRA activation. Activated PDGFRA and EGFR frequently coexist with amplification and overexpression of the MDM2 oncogene. Ex vivo immunoassays on primary IS cells from one case showed the potency of dasatinib to inhibit PDGFRA and downstream signaling pathways. Our findings provide a rationale for investigating therapies that target PDGFRA, EGFR, or MDM2 in IS. Given the clonal heterogeneity of this tumor type and the potential cross-talk between the PDGFRA and EGFR signaling pathways, targeting multiple RTKs and aberrant downstream effectors might be required to improve the therapeutic outcome for patients with this disease.
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/10/2010 10:48
Dernière modification de la notice
20/08/2019 14:57
Données d'usage